UNSPSC 51386004: Butanixin

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FZ99TBX0LI. European Medicines Agency schedules Butanixin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06004MIG. Butanixin generally arises in the molecular formula C16H18N2O2.

UNSPSC 51386004 Butanixin is a Commodity code that maps inconsistently to actual state and local procurement activity. The three recent opportunities tagged under this code—Seminole County's Naloxone and drug deactivation systems procurement, Texas HHS's Therapeutic Pharmacy Initiative RFI, and MMCAP's generic pharmaceuticals RFP—cover naloxone, prescription fulfillment systems, and generic OTC products, none of which constitute butanixin. State and local governments show no recent solicitations for butanixin itself under this code. The opportunities instead reflect procurement for opioid-response pharmaceuticals (naloxone), pharmacy benefit management infrastructure, and broad generic pharmaceutical supply agreements spanning multiple wholesalers and state health systems.

Recent activity under this code appears concentrated in state health agencies and regional cooperative purchasing vehicles rather than traditional county or municipal health departments. Seminole County, Florida issued an IFB on June 30, 2026 for 1,900 units of naloxone and 800 drug deactivation systems annually with a response deadline of July 26, 2023 (note: deadline date is inconsistent with posting date). The Texas Health and Human Services Commission posted an RFI on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer pharmacy programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP on January 20, 2026 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon. Geographic activity centers on Florida, Texas, and the MMCAP footprint (Minnesota and Oregon named). Given the code-to-scope mismatch, businesses should verify actual procurement intent against the butanixin code designation in issuing-body notices before committing resources.